Diversigen nabs Novartis veteran for board position; MediVet opens second U.S. lab; Valneva teams with Fatro for veterinary vaccines;

> Diversigen, which provides microbiome and metagenomic services to the animal health industry, appointed George Gunn, formerly of Novartis ($NVS) Animal Health, to its board of directors. Release

> Regenerative medicine company MediVet Biologics announced it will open its second U.S. laboratory in Manhattan, KS, this October. Release

> Vaccine maker Valneva of France signed a licensing agreement with Italian pharmaceutical company Fatro to develop and commercialize two veterinary vaccines using its EB66 cells. Release

> India's Lyka Labs announced it is selling its animal health division to Alivira Animal Health for an undisclosed sum. Article

> A new report from BCC Research predicts that the U.S. market for pet care products and services will grow at a compound annual rate of 2.5% through 2020 to $69.4 billion. Release

> Premune has formed a licensing agreement with Innovet Italia to bring its product Redonyl Ultra, a skin supplement for dogs and cats, to European markets outside of Italy, with an option to introduce the product in North America. Release

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…